MiNK Therapeutics Management
Management criteria checks 3/4
MiNK Therapeutics' CEO is Jen Buell, appointed in Feb 2021, has a tenure of 3.75 years. total yearly compensation is $2.81M, comprised of 16.1% salary and 83.9% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $168.09K. The average tenure of the management team and the board of directors is 3.3 years and 5.5 years respectively.
Key information
Jen Buell
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 16.1% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$3m | US$451k | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$26m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$4m | US$424k | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$233k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$917 | n/a | -US$16m |
Compensation vs Market: Jen's total compensation ($USD2.81M) is above average for companies of similar size in the US market ($USD646.00K).
Compensation vs Earnings: Jen's compensation has been consistent with company performance over the past year.
CEO
Jen Buell (49 yo)
3.8yrs
Tenure
US$2,807,439
Compensation
Dr. Jennifer S. Buell, also known as Jen, Ph.D. is a Director at Agenus Inc since June 11, 2024. She has been Independent Director at Protagenic Therapeutics, Inc. since July 18, 2020. Dr. Buell served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.3yrs | US$344.32k | 4.37% $ 1.3m | |
| President | 3.8yrs | US$2.81m | 0.59% $ 168.1k | |
| Treasurer | 7.3yrs | US$29.62k | 0.14% $ 40.3k | |
| Director of Legal & Business Affairs | less than a year | no data | no data | |
| Vice President & Head of CMC | 2.8yrs | no data | no data |
3.3yrs
Average Tenure
58yo
Average Age
Experienced Management: INKT's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.3yrs | US$344.32k | 4.37% $ 1.3m | |
| President | 3.8yrs | US$2.81m | 0.59% $ 168.1k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$106.95k | 0.97% $ 277.8k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$154.75k | 0.97% $ 277.7k | |
| Independent Director | 3.2yrs | US$154.25k | 0.26% $ 75.6k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$111.45k | 0.23% $ 65.5k | |
| Member of the Scientific Advisory Board | no data | no data | no data |
5.5yrs
Average Tenure
64yo
Average Age
Experienced Board: INKT's board of directors are considered experienced (5.5 years average tenure).